Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876008 | 0.83 | LOXL2 (0.41) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13875945 | 0.83 | RAB9A (0.61) | GRM5RAB9AGALR3MAPK1NPC1 | |
| SCHEMBL13890809 | 0.82 | GRM5 (0.50) | GRM5RAB9AGALR3MAPK1NPC1 | |
| SCHEMBL13876048 | 0.79 | ABL1 (0.43) | MAPT | |
| SCHEMBL13875986 | 0.78 | LOXL2 (0.42) | L3MBTL1KMT2A | |
| SCHEMBL13876011 | 0.78 | KDM4E (0.42) | MAPK1LMNA | |
| SCHEMBL13875991 | 0.78 | HRH3 (0.48) | GRM5KMT2A | |
| SCHEMBL13876002 | 0.78 | NR1H2 (0.43) | — | |
| SCHEMBL13876045 | 0.76 | EPHX2 (0.43) | RAB9ANPC1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13875994 | 0.75 | PARP15 (0.43) | RAB9AMAPK1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | GRM5 3574/4885RAB9A 2900/4885GALR3 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.